Pinterest Inc vs Recursion Pharmaceuticals Inc — how do they compare? Pinterest Inc trades at $22.54 (market cap $12.79B), while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Pinterest Inc is far larger — about 7.8× Recursion Pharmaceuticals Inc's market cap, and Pinterest Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PINS | RXRX | |
|---|---|---|
Market Cap | $12.79B | $1.63B |
Sector | Media | Health |
52-Week High | $39.17 | $6.79 |
52-Week Low | $15.42 | $2.84 |
Enterprise Value | $12.69B | $1.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Trailing returns across standard periods
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →